Criteria
| Eligible Active Ingredient: | Desloratadine Syrup. As an oral liquid preparation containing not more than 0.5mg/ml |
| With Effective From: | 1-Jul-2011 |
| Indication Permitted: | For relief of symptoms associated with allergic rhinitis and urticaria. Dosing regimen: 12 years and above: 5mg once daily 6-11 years: 2.5 mg once daily 2-5 years: 1.25 mg once daily |
| Maximum Daily Dose: | 12 years and above: 5mg 6-11 years: 2.5 mg 2-5 years: 1.25 mg |
| Maximum Supply per Transaction: | 2 weeks |
| Minimum Age of User: | 2 years |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Desloratadine Syrup
Like other H1-blockers, Desloratadine competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.
Additional Information of Desloratadine Syrup
| Pharmacology Class: | Antihistamines For Systemic Use |
| Therapeutic Class: | Antihistamines For Systemic Use |
| Chemical Class: | Other Antihistamines For Systemic Use |
| Synonyms: | 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine | 8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine | Descarboethoxyloratadine | DESLORATADINE |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Desloratadine Syrup As an oral liquid preparation containing not more than 0.5mg/ml
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.